Integra Lifesciences Holdings (STU:IL3) PEG Ratio: N/A (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IL3 Integra Lifesciences Holdings Corp STU:IL3
74 GF Score
Price €16.40
GF Value €20.79
Valuation Modestly Undervalued
! 11 Warning Signs
View Full Analysis

What is Integra Lifesciences Holdings PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Integra Lifesciences Holdings's PE Ratio without NRI is 8.09. Integra Lifesciences Holdings's 5-Year EBITDA growth rate is 0.00%. Therefore, Integra Lifesciences Holdings's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Integra Lifesciences Holdings's PEG Ratio or its related term are showing as below:


During the past 13 years, Integra Lifesciences Holdings's highest PEG Ratio was 210.56. The lowest was 0.78. And the median was 2.70.


STU:IL3's PEG Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.01
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Integra Lifesciences Holdings  (STU:IL3) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Integra Lifesciences Holdings PEG Ratio Related Terms


Integra Lifesciences Holdings PEG Ratio Historical Data

* Premium members only.

The historical data trend for Integra Lifesciences Holdings's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integra Lifesciences Holdings PEG Ratio Chart

Integra Lifesciences Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.32 0.86 1.29 0.00 0.00

Integra Lifesciences Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:IL3 vs ATEC, AHCO, INSP: PEG Ratio Comparison

For the Medical Devices subindustry, Integra Lifesciences Holdings's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integra Lifesciences Holdings PEG Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Integra Lifesciences Holdings's PEG Ratio falls into.


STU:IL3
74GF Score
Integra Lifesciences Holdings Corp STU:IL3
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integra Lifesciences Holdings PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Integra Lifesciences Holdings's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=8.0947680157947/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Integra Lifesciences Holdings (STU:IL3) Overvalued in 2026?

Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued. The current stock price of €16.40 is trading 21.1% below its estimated GF Value™ of €20.79. GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.

Key valuation signals for STU:IL3:

  • PEG Ratio: N/A
  • GF Value™: €20.79 vs. price of €16.40 (21.1% below fair value)
  • GF Score™: 74/100 with 11 warning signs

No single metric tells the full story. See the STU:IL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Integra Lifesciences Holdings Business Description

Other Exchanges IART:USA
Address 1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
74GF Score

Get the complete analysis for STU:IL3

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.40
Price
€20.79
GF Value